

Corporate Fact Sheet

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody technologies.

Company Highlights

- Emerging leader in developing immuno-oncology therapeutics
- Differentiated pipeline comprising eight clinical-stage product candidates
- Leading multispecific antibody technology platforms, with six clinical DART molecules
- Fully-integrated mAb-based development capabilities, including GMP manufacturing
- Collaborations with Janssen, Takeda, Servier, Boehringer Ingelheim and Pfizer
- Experienced management team and highly collaborative corporate culture

Pipeline

Program (Target)	Indication	Pre-IND	Phase 1	Phase 2	Phase 3	Partner
ONCOLOGY						
Margetuximab (HER2)	Breast (HER2+) "SOPHIA"					Green Cross (Korea only)
	Gastric (+pembrolizumab)					
	Breast (low HER2)					
Enoblituzumab (B7-H3)	Solid Tumors (mono.)					—
	Solid Tumors (+ipi)					
	Solid Tumors (+pembro.)					
MGD006 (CD123 x CD3)	AML/MDS					Servier (EU, Other)
MGD007 (gpA33 x CD3)	Colorectal					
MGD011 (CD19 x CD3)	B-cell Malignancies					Janssen (WW)*
MGD009 (B7-H3 x CD3)	Solid Tumors					—
MGA012	Solid Tumors/Heme					—
MGD013 (PD-1 x LAG-3)	Solid Tumors/Heme					—
AUTOIMMUNE & INFECTIOUS DISEASES						
Teplizumab (CD3)	Type 1 Diabetes Prev.					NIDDK/NIH
MGD010 (CD32B x CD79B)	Autoimmune Disorders					—
MGD014 (HIV x CD3)	HIV					NIAID/NIH
* MacroGenics retains co-promotion rights for MGD011 in U.S.						DART mAb

MacroGenics' Antibody Formats

Dual-Affinity Re-Targeting, or DART[®], and Trident[™] therapeutics enable the targeting of multiple antigens or cells with a single antibody-like molecule. Applications include the recruitment of a patient's T cells to destroy targeted cancer cells and the engagement of two checkpoint inhibitors for improved activation of the immune system. The flexibility of this platform allows for the design of molecules with increased half-life and valency compared to other multi-specific approaches.

Fc-Optimized antibodies mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells.

Quick Facts

Employees:
303 (as of 8/31/16)

Cash & Investments:
\$341M (Pro Forma) at 6/30/16
(reflecting \$75M from Janssen in early 3Q16)

Shares Outstanding:
34.7M at 6/30/16

Ticker:
MGNX (NASDAQ)

Locations:
Rockville, MD
South San Francisco, CA

Platforms:
DART[®] (bispecific)
Trident[™] (trispecific)
Fc Optimization
Cancer Stem-like Cells

Key Collaborations

MacroGenics has developed significant alliances with leading pharmaceutical and biotechnology companies. Ongoing collaboration partners that have provided significant non-dilutive funding include:



May 2016 & Dec. 2014



September 2014



September 2012



October 2010



October 2010

Management

Scott Koenig, M.D., Ph.D.
President and CEO

James Karrels
Senior Vice President, CFO

Ezio Bonvini, M.D.
Senior Vice President, Research
and Chief Scientific Officer

Eric Risser
Senior Vice President,
Bus. Dev. and Port. Mgmt. &
Chief Business Officer

Atul Saran
Senior Vice President and
General Counsel

Tom Spitznagel, Ph.D.
Senior Vice President,
BioPharmaceutical
Dev't and Manufac turing

Jon Wigginton, M.D.
Senior Vice President,
Clinical Development &
Chief Medical Officer

Syd Johnson, Ph.D.
Vice President,
Antibody Engineering

Paul Moore, Ph.D.
Vice President,
Immunology & Cell Biology

James Vasselli, M.D.
Vice President,
Clinical Research

Board of Directors

Paulo Costa (Chairman)
Former President & CEO,
Novartis Pharmaceuticals, US

Matthew Fust
Former CFO,
Onyx Pharmaceuticals

Kenneth Galbraith
General Partner,
Five Corners Capital

Edward Hurwitz
Managing Director,
Precision BioVentures

Scott Koenig, M.D., Ph.D.
President and CEO,
MacroGenics

David Stump, M.D.
Former EVP of R&D,
Human Genome Sciences


Clinical Product Candidates

Margetuximab (HER2) Fc-optimized mAb Phase 3

Margetuximab is an Fc-optimized mAb that targets HER2-expressing tumors, including breast and gastroesophageal cancers. MacroGenics has engineered the Fc region of margetuximab to enhance its Fc-mediated effects, including improved ADCC. The Company is conducting a Phase 3 registration trial (SOPHIA) in mBC patients to demonstrate clinical superiority to trastuzumab. The Company is also enrolling a Phase 1b/2 study for the treatment of advanced gastric cancer, in which margetuximab is used in combination with pembrolizumab.

B7-H3 Programs

MacroGenics is developing a portfolio of first-in-class therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation and believed to inhibit T-cell activation. The Company's two clinical programs target B7-H3 through complementary mechanisms of action and take advantage of this antigen's broad expression across solid tumors but limited on normal tissues.



Adapted from Pardoll, et al., Nature, April 2012.

Enoblituzumab (B7-H3) Fc-optimized mAb Phase 1b/2

Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3. The company is enrolling patients in multiple Phase 1 monotherapy cohorts evaluating seven solid tumors, including prostate, bladder, melanoma and others. The Company also continues to enroll patients in two combination studies with either ipilimumab or pembrolizumab.

MGD009 (B7-H3 x CD3) Fc-bearing DART Phase 1

MGD009 is a DART molecule that recognizes both B7-H3 and CD3. MGD009 is designed to redirect T cells, via their CD3 component, to eliminate cells expressing B7-H3, which is expressed by tumor cells, and on tumor-associated vasculature, stroma and certain tumor-associated leukocytes. MGD009 is being tested in a Phase 1 study in multiple solid tumor types.

Other DART Programs

MGD006 (CD123 x CD3) DART Phase 1

MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. MacroGenics is enrolling refractory, relapsing AML and MDS patients in a Phase 1 clinical trial.

MGD007 (gpA33 x CD3) Fc-bearing DART Phase 1

MGD007 is a humanized DART molecule that recognizes both gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors, including more than 95% of human colorectal cancers. The Company is enrolling patients with metastatic colorectal cancer in a Phase 1 clinical trial.

MGD011 (CD19 x CD3) Fc-bearing DART Phase 1

MGD011 (also known as JNJ-64052781 or duvortuxizumab) is a humanized DART molecule that recognizes both CD19 and CD3 and is being developed for the treatment of B-cell hematological malignancies. MacroGenics licensed worldwide rights to MGD011 to Janssen Biotech, Inc. in early 2015, and retains a U.S. co-promote. Janssen is responsible for clinical development of MGD011.

MGD010 (CD32B x CD79B) Fc-bearing DART Phase 1

MGD010 is a humanized DART molecule that simultaneously recognizes both CD32B and CD79B, two B-cell surface proteins, for the treatment of autoimmune disorders. MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells. Encouraging Phase 1 data was presented at 2016 EULAR.

© 2016 MacroGenics, Inc. All rights reserved. The information in this fact sheet is current as of August 3, 2016, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein.